Developer docs
API playgroundTry for free, no card

Search company profiles

Q-linea

Full company profile

uuid0006f1f

Namestring
Q-linea
Legal namestring
Q-linea AB
Websiteurl
qlinea.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Q-linea AB is a Swedish medical technology company headquartered in Uppsala, founded in 2008, and publicly listed on Nasdaq Stockholm under the ticker QLINEA. The company develops and commercializes the ASTar system, a CE-IVD marked rapid antibiotic susceptibility testing (AST) platform designed for hospital clinical microbiology laboratories. ASTar delivers results in approximately 6 hours directly from positive blood cultures, compared with approximately 48 hours for traditional AST methods, addressing a critical bottleneck in sepsis treatment and antimicrobial resistance management. The system combines automated sample preparation with high-content imaging and algorithm-based interpretation, accelerated by NVIDIA GPU computing (CUDA, cuDNN, TensorRT), to produce accurate minimum inhibitory concentration (MIC) values.

Q-linea's commercial product portfolio centers on the ASTar instrument, the ASTar Kit (sample preparation cassettes and discs), and the Podler accessory. Revenue is generated through capital instrument sales, recurring consumables, and flexible commercial models including instrument rental and reagent rental, with 6-12 week typical installation lead times. The company distributes primarily through direct enterprise sales to hospital laboratories, supplemented by a distributor portal for channel partners. As of December 2025, ASTar has been implemented at two initial US hospital systems alongside established European reference customers such as Uppsala University Hospital, with dedicated US sales and support infrastructure already in place. The company is pursuing US FDA 510(k) clearance, holds ISO 13485:2016 certification, and has supplemented its capital structure with rights issues in 2024 and 2025 alongside its Nasdaq Stockholm listing.

The company serves hospital clinical laboratories, infectious disease clinicians, and antimicrobial stewardship programs. Clinical evidence presented at ASM Microbe 2025 demonstrated 95.7% categorical agreement for antibiotic-resistant organisms and potential to enable earlier treatment de-escalation in 59% of cases. Leadership includes founder/CEO Jonas Jarvius together with functional CXOs covering finance, science, operations, commercial, technology, and medical affairs; an interim CFO was appointed during the 2025 capital-raising and US expansion phase.

Short descriptiontext

Q-linea AB (Nasdaq Stockholm: QLINEA) is a Swedish medical technology company that develops and commercializes ASTar, a CE-IVD marked rapid antibiotic susceptibility testing system delivering results in approximately 6 hours for hospital clinical laboratories managing sepsis and bloodstream infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid antibiotic susceptibility testing, clinical microbiology diagnostics, blood culture analysis systems, sepsis diagnostic instruments, antimicrobial resistance testing
Industry1 code
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics / Clinical Microbiology Instruments
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1ASTar Instrument Sales
TypeHardware Sales
Description

Capital purchase of ASTar instruments to hospital laboratories. The instrument is sold directly to healthcare institutions for installation in clinical microbiology labs. This represents the primary revenue driver for initial customer acquisition.

qlinea.com
2Reagent and Consumables Sales
TypeSubscription Recurring
Description

Recurring revenue from sale of ASTar kits including sample preparation cassettes and AST discs. These consumables are required for each test run, creating recurring revenue from the installed instrument base.

qlinea.com
3Rental and Reagent Rental Models
TypeManaged Services
Description

Alternative commercial models including rental of instruments and reagent rental arrangements. These flexible options reduce upfront capital requirements for hospital customers and provide predictable recurring revenue streams.

qlinea.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Capital Purchase - Direct instrument acquisition
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Hospitals can purchase the ASTar instrument outright. No public pricing available; quote-based sales process.

qlinea.com
2Rental Model - Instrument leasing option
ModelSubscriptionBilling cadenceMonthly
Notes

Flexible rental option for hospitals that prefer not to make capital expenditure. Terms negotiated individually.

qlinea.com
3Reagent Rental - Consumables-based model
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Instrument provided with commitment to purchase reagents/consumables. Aligns with ongoing consumable revenue model.

qlinea.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Q-linea develops, manufactures, and sells the ASTar system, a CE-IVD marked rapid antibiotic susceptibility testing (AST) instrument that is fully automated and delivers results directly from positive blood cultures in approximately 6 hours. The company also sells proprietary consumables (ASTar Kit cassettes and discs) required to operate the instrument, generating recurring revenue from the installed base of hospital laboratory customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95.7% categorical agreement for antibiotic-resistant organisms in AST
+3 more records
Product overview1 text field

Q-linea offers a focused diagnostic product portfolio centered on the ASTar system, a rapid antibiotic susceptibility testing platform designed to improve sepsis treatment outcomes. ASTar is a fully automated instrument that works directly with positive blood cultures, delivering results in approximately 6 hours compared to traditional methods that can take 48 hours or more. The product line includes the core ASTar instrument, ASTar Kit (sample preparation cassettes and discs), and Podler accessory. All products are designed for hospital laboratory use to help determine optimal antibiotic treatment for patients with bloodstream infections.

Product and service3 records
1ASTar System
CategoryIn Vitro Diagnostics - Clinical Microbiology Instruments
Description

A CE-IVD marked rapid antibiotic susceptibility testing (AST) system that is fully automated and delivers results directly from positive blood cultures in approximately 6 hours. Designed for use in hospital clinical microbiology laboratories to determine the best antibiotic treatment for patients with sepsis and bloodstream infections.

2ASTar Kit
CategoryIn Vitro Diagnostics - Reagents and Consumables
Description

Proprietary consumable kit for the ASTar system including sample preparation cassettes and discs required to obtain AST results directly from clinical samples. Sold as a recurring consumable to hospital laboratory customers operating the ASTar instrument.

3Podler
CategoryIn Vitro Diagnostics - Instrument Accessories
Description

Accessory component of the ASTar system, supporting the broader ASTar workflow in hospital laboratory settings.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

NVIDIA provides GPU computing technology (CUDA, cuDNN, TensorRT) that powers ASTar's image analysis and machine learning capabilities. The third-party licenses page documents extensive NVIDIA software components integrated into the ASTar system for accelerated computing tasks.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Offers a broad clinical microbiology and blood-culture workflow portfolio (including the cobas systems) and serves the same hospital lab decision-makers as Q-linea, providing competitive context for AST purchasing decisions.

TypeDirect peer
Description

Develops the Accelerate Pheno system, a rapid AST platform that delivers phenotypic susceptibility results from positive blood cultures in hours. Directly comparable to Q-linea's ASTar in clinical use case, target customer (hospital microbiology labs), and rapid-from-blood-culture workflow.

3Beckman Coulter
TypeBroad incumbent
Description

Provides the MicroScan WalkAway AST system widely used in hospital microbiology labs. A direct workflow competitor to ASTar and part of a broader diagnostics portfolio that gives Beckman Coulter cross-selling advantages.

TypeEmerging player
Description

Develops the Next Generation Phenotyping (NGP) rapid AST platform intended to deliver same-shift AST from clinical samples. A focused emerging competitor in the same rapid AST category as ASTar.

TypeBroad incumbent
Description

Global leader in clinical microbiology with the VITEK 2 AST system and BACT/ALERT blood culture portfolio. Competes head-to-head with ASTar in hospital microbiology labs and has the installed base, menu breadth, and reimbursement leverage that Q-linea must displace.

TypeBroad incumbent
Description

Sells the MALDI Biotyper for microbial ID and the MBT Sepsityper workflow that accelerates ID directly from positive blood cultures. Often used alongside AST in clinical microbiology, making Bruker an adjacent incumbent in the workflow Q-linea targets.

TypeEmerging player
Description

Develops a rapid phenotypic AST system using proprietary sensor-based detection of bacterial metabolism. Competes with Q-linea in the rapid AST-for-bloodstream-infections niche but at an earlier commercial stage.

TypeOthers
Description

Leading manufacturer of pre-analytical microbiology sample collection and transport products used in hospital labs running AST. Functionally adjacent as a workflow partner/supplier feeding the same microbiology pipeline Q-linea serves.

TypeDirect peer
Description

Develops rapid molecular diagnostics (T2Candida, T2Bacteria) for bloodstream infections direct from whole blood. Targets the same sepsis-decision-support use case as ASTar, albeit via a molecular rather than phenotypic approach.

TypeBroad incumbent
Description

Sells the BD Phoenix M50 AST system and BD MAX molecular platform, alongside a leading blood culture franchise. Overlaps with Q-linea across hospital AST workflows and benefits from a much larger sales, support, and menu footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q-linea

In Vitro Diagnostics / Clinical Microbiology Instrumentsqlinea.com

Q-linea AB (Nasdaq Stockholm: QLINEA) is a Swedish medical technology company that develops and commercializes ASTar, a CE-IVD marked rapid antibiotic susceptibility testing system delivering results in approximately 6 hours for hospital clinical laboratories managing sepsis and bloodstream infections.

What Q-linea does

Q-linea AB is a Swedish medical technology company headquartered in Uppsala, founded in 2008, and publicly listed on Nasdaq Stockholm under the ticker QLINEA. The company develops and commercializes the ASTar system, a CE-IVD marked rapid antibiotic susceptibility testing (AST) platform designed for hospital clinical microbiology laboratories. ASTar delivers results in approximately 6 hours directly from positive blood cultures, compared with approximately 48 hours for traditional AST methods, addressing a critical bottleneck in sepsis treatment and antimicrobial resistance management. The system combines automated sample preparation with high-content imaging and algorithm-based interpretation, accelerated by NVIDIA GPU computing (CUDA, cuDNN, TensorRT), to produce accurate minimum inhibitory concentration (MIC) values.

Q-linea's commercial product portfolio centers on the ASTar instrument, the ASTar Kit (sample preparation cassettes and discs), and the Podler accessory. Revenue is generated through capital instrument sales, recurring consumables, and flexible commercial models including instrument rental and reagent rental, with 6-12 week typical installation lead times. The company distributes primarily through direct enterprise sales to hospital laboratories, supplemented by a distributor portal for channel partners. As of December 2025, ASTar has been implemented at two initial US hospital systems alongside established European reference customers such as Uppsala University Hospital, with dedicated US sales and support infrastructure already in place. The company is pursuing US FDA 510(k) clearance, holds ISO 13485:2016 certification, and has supplemented its capital structure with rights issues in 2024 and 2025 alongside its Nasdaq Stockholm listing.

The company serves hospital clinical laboratories, infectious disease clinicians, and antimicrobial stewardship programs. Clinical evidence presented at ASM Microbe 2025 demonstrated 95.7% categorical agreement for antibiotic-resistant organisms and potential to enable earlier treatment de-escalation in 59% of cases. Leadership includes founder/CEO Jonas Jarvius together with functional CXOs covering finance, science, operations, commercial, technology, and medical affairs; an interim CFO was appointed during the 2025 capital-raising and US expansion phase.

Q-linea firmographics

Firmographics
Name
Q-linea
Legal name
Q-linea AB
Website
https://qlinea.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
Q-linea AB (Nasdaq Stockholm: QLINEA) is a Swedish medical technology company that develops and commercializes ASTar, a CE-IVD marked rapid antibiotic susceptibility testing system delivering results in approximately 6 hours for hospital clinical laboratories managing sepsis and bloodstream infections.
Ownership category
akta.pro rank

Q-linea industry classification

Industry
Product category
In Vitro Diagnostics / Clinical Microbiology Instruments
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Rapid antibiotic susceptibility testing
  • Clinical microbiology diagnostics
  • Blood culture analysis systems
  • Sepsis diagnostic instruments
  • Antimicrobial resistance testing

Where Q-linea is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Q-linea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ASTar Instrument Sales: Capital purchase of ASTar instruments to hospital laboratories. The instrument is sold directly to healthcare institutions for installation in clinical microbiology labs. This represents the primary revenue driver for initial customer acquisition.
  2. Reagent and Consumables Sales: Recurring revenue from sale of ASTar kits including sample preparation cassettes and AST discs. These consumables are required for each test run, creating recurring revenue from the installed instrument base.
  3. Rental and Reagent Rental Models: Alternative commercial models including rental of instruments and reagent rental arrangements. These flexible options reduce upfront capital requirements for hospital customers and provide predictable recurring revenue streams.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseCapital Purchase - Direct instrument acquisition
SubscriptionMonthlyRental Model - Instrument leasing option
Usage-basedPay-as-you-goReagent Rental - Consumables-based model

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Q-linea product offering

Product offering

Core offering

Q-linea develops, manufactures, and sells the ASTar system, a CE-IVD marked rapid antibiotic susceptibility testing (AST) instrument that is fully automated and delivers results directly from positive blood cultures in approximately 6 hours. The company also sells proprietary consumables (ASTar Kit cassettes and discs) required to operate the instrument, generating recurring revenue from the installed base of hospital laboratory customers.

Product overview

Q-linea offers a focused diagnostic product portfolio centered on the ASTar system, a rapid antibiotic susceptibility testing platform designed to improve sepsis treatment outcomes. ASTar is a fully automated instrument that works directly with positive blood cultures, delivering results in approximately 6 hours compared to traditional methods that can take 48 hours or more. The product line includes the core ASTar instrument, ASTar Kit (sample preparation cassettes and discs), and Podler accessory. All products are designed for hospital laboratory use to help determine optimal antibiotic treatment for patients with bloodstream infections.

Differentiator

Problem solved

Functional benefit

Products and services

  • ASTar System A CE-IVD marked rapid antibiotic susceptibility testing (AST) system that is fully automated and delivers results directly from positive blood cultures in approximately 6 hours. Designed for use in hospital clinical microbiology laboratories to determine the best antibiotic treatment for patients with sepsis and bloodstream infections.
  • ASTar Kit Proprietary consumable kit for the ASTar system including sample preparation cassettes and discs required to obtain AST results directly from clinical samples. Sold as a recurring consumable to hospital laboratory customers operating the ASTar instrument.
  • Podler Accessory component of the ASTar system, supporting the broader ASTar workflow in hospital laboratory settings.

Quantifiable outcome

  • 95.7% categorical agreement for antibiotic-resistant organisms in AST
  • +3 more outcomes

Companies that use Q-linea

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Q-linea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Q-linea partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NVIDIAcoreTechnology or IntegrationNVIDIA provides GPU computing technology (CUDA, cuDNN, TensorRT) that powers ASTar's image analysis and machine learning capabilities. The third-party licenses page documents extensive NVIDIA software components integrated into the ASTar system for accelerated computing tasks.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Q-linea competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics: Offers a broad clinical microbiology and blood-culture workflow portfolio (including the cobas systems) and serves the same hospital lab decision-makers as Q-linea, providing competitive context for AST purchasing decisions.
  • Beckman Coulter: Provides the MicroScan WalkAway AST system widely used in hospital microbiology labs. A direct workflow competitor to ASTar and part of a broader diagnostics portfolio that gives Beckman Coulter cross-selling advantages.
  • bioMérieux: Global leader in clinical microbiology with the VITEK 2 AST system and BACT/ALERT blood culture portfolio. Competes head-to-head with ASTar in hospital microbiology labs and has the installed base, menu breadth, and reimbursement leverage that Q-linea must displace.
  • Bruker: Sells the MALDI Biotyper for microbial ID and the MBT Sepsityper workflow that accelerates ID directly from positive blood cultures. Often used alongside AST in clinical microbiology, making Bruker an adjacent incumbent in the workflow Q-linea targets.
  • Becton Dickinson (BD): Sells the BD Phoenix M50 AST system and BD MAX molecular platform, alongside a leading blood culture franchise. Overlaps with Q-linea across hospital AST workflows and benefits from a much larger sales, support, and menu footprint.

Direct peers

  • Accelerate Diagnostics: Develops the Accelerate Pheno system, a rapid AST platform that delivers phenotypic susceptibility results from positive blood cultures in hours. Directly comparable to Q-linea's ASTar in clinical use case, target customer (hospital microbiology labs), and rapid-from-blood-culture workflow.
  • T2 Biosystems: Develops rapid molecular diagnostics (T2Candida, T2Bacteria) for bloodstream infections direct from whole blood. Targets the same sepsis-decision-support use case as ASTar, albeit via a molecular rather than phenotypic approach.

Emerging players

  • Selux Diagnostics: Develops the Next Generation Phenotyping (NGP) rapid AST platform intended to deliver same-shift AST from clinical samples. A focused emerging competitor in the same rapid AST category as ASTar.
  • Specific Diagnostics: Develops a rapid phenotypic AST system using proprietary sensor-based detection of bacterial metabolism. Competes with Q-linea in the rapid AST-for-bloodstream-infections niche but at an earlier commercial stage.

Others

  • Copan Diagnostics: Leading manufacturer of pre-analytical microbiology sample collection and transport products used in hospital labs running AST. Functionally adjacent as a workflow partner/supplier feeding the same microbiology pipeline Q-linea serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Q-linea social profiles

Digital presence

Q-linea compliance and trust

Trust signal

Compliance1 record

Q-linea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q-linea leadership team

Management profile

Number of profiles

Profiles9 records

Q-linea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q-linea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q-linea

What does Q-linea do?

Q-linea develops, manufactures, and sells the ASTar system, a CE-IVD marked rapid antibiotic susceptibility testing (AST) instrument that is fully automated and delivers results directly from positive blood cultures in approximately 6 hours. The company also sells proprietary consumables (ASTar Kit cassettes and discs) required to operate the instrument, generating recurring revenue from the installed base of hospital laboratory customers.

Is Q-linea a public or private company?

Q-linea is a public company. It is classified as public and is currently operating.

When was Q-linea founded?

Q-linea was founded in 2008. It employs 51 to 100 people.

Where is Q-linea based?

Q-linea is headquartered in Uppsala, Sweden, in the Europe region.

How does Q-linea make money?

Three revenue lines are on record. ASTar Instrument Sales are the primary driver. The others are reagent and Consumables Sales and rental and Reagent Rental Models.

Who are Q-linea's main competitors?

Broad incumbents on record are Roche Diagnostics, Beckman Coulter, bioMérieux, Bruker and Becton Dickinson (BD). Direct peers are Accelerate Diagnostics and T2 Biosystems. Emerging players are Selux Diagnostics and Specific Diagnostics. Copan Diagnostics is listed as an others.

Does Q-linea have an API?

No public API is recorded for Q-linea.

What industry is Q-linea in?

Q-linea's product category is In Vitro Diagnostics / Clinical Microbiology Instruments. Its primary akta.pro industry code is HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables). Its NAICS code is 33451 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewQ-linea Q3 2026 Earnings Call Is LiveQ-linea's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.Dagens industriNy förlust för Q-LineaQ-Linea reported an operating loss of 30.6 million Swedish kronor for the third quarter of 2026, down from 40.7 million in the prior quarter. The medical technology company's loss narrowed, but the figure remains negative.MarketScreenerQ-linea Receives New US Contract for Antimicrobial Susceptibility Testing SystemQ-linea AB has secured a new contract in the United States for its ASTar antimicrobial susceptibility testing system. The device is designed to identify sepsis in hospital patients by providing susceptibility profiles within three to six hours from positive blood cultures. This agreement marks a commercial expansion for the Sweden-based medical technology company into the US market.Investing.comEarnings call transcript: Q-linea narrows loss in Q2 2026 as stock rises 6.8% By Investing.comQ-linea reported Q2 2026 results showing a narrowed operating loss of SEK 31.3 million, down from SEK 47.4 million a year earlier, while net sales rose to SEK 1.5 million from SEK 0.5 million. The Swedish diagnostics company completed its restructuring by consolidating to a single site in Sweden and expanded its contracted ASTar instrument base to 24 units from 12 a year ago, with 21 instruments now active in clinical use. The stock rose 6.83% to $17.2 in premarket trading as investors responded positively to the cost improvements and FDA approval of its expanded ASTar menu.Dagens industriQ-Lineas förlust minskarQ-Linea, a company operating in infection diagnostics, reported its second quarter 2026 financial results showing a reduced operating loss of -31.3 million SEK compared to -47.3 million SEK in the same period the previous year. Net sales increased to 1.5 million SEK from 1.1 million SEK year-over-year, indicating improved operational performance. The results were published on July 10, 2026.MarketScreenerQ-linea secures FDA clearance for expanded ASTar panelQ-linea received FDA clearance for an expanded ASTar panel, adding new antibiotics and enhanced algorithms. The panel aligns with latest FDA breakpoints and is tailored for laboratories and clinics. CEO Stuart Gander said it mirrors ASTar's CE-IVDR-certified offerings in Europe and other markets.MarketScreenerQ-linea Implements ASTar at Two Initial Hospital Systems in the United StatesQ-linea AB, a Swedish medical technology company, has implemented its ASTar Antibiotic Susceptibility Testing instrument in two hospital systems in the United States. The product offers rapid bacterial susceptibility profiles, supporting early targeted antibiotic treatment for sepsis patients.IdseMeningitis Diagnostics RealTime PCR Assays EvaluationA study presented at ESCMID 2025 found that real-time PCR assays from bioMérieux, Qiagen, and Seegene demonstrated strong performance in detecting key bacterial meningitis pathogens from cerebrospinal fluid samples, with preliminary data supporting extraction-free testing. Separately, research at ASM Microbe 2025 showed Q-linea's ASTar System achieved 95.7% categorical agreement for antibiotic-resistant organisms in antimicrobial susceptibility testing, with potential to enable earlier treatment de-escalation in 59% of cases. The FDA granted 510(k) clearance for Hologic's Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays, enabling rapid molecular testing for common gastroenteritis-causing bacteria.news.cision.comWebinar Tuesday November 10th: Equal and better care for everyoneQ-linea AB will host a webinar on November 10th at 17:00 CET, featuring presentations and a Q&A with its CEO and directors. The agenda covers ASTar's lab and clinic challenges, an upcoming product, and Q&A. The webinar will be available on-demand.news.cision.comQ-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical studyQ-linea announced that Hvidovre Hospital in Denmark will participate in its European pivotal clinical study for ASTar, starting autumn 2020. The study will involve 80-100 patients across Q-linea, Hvidovre, and Uppsala University Hospital, with results supporting CE-IVD approval for ASTar's market launch.